Carboplatin/Pegylated Liposomal Doxorubicin/Bevacizumab (CD-Bev) vs. Carboplatin/Gemcitabine/Bevacizumab (CG-BEV) in Patients with Recurrent Ovarian Cancer: a Prospective Randomized Phase iii Engot/GCiG-Intergroup Study (Ago Study Group, Ago-AUSTRiA, ANZGOG,GiNECO, SGCTG)

Hanker L, Harter P, Sehoul L, Rau J, Canzler U, Schmalfeldt B, Thiel F, El-Balat A, Marme F, De Gregorio N, Baumannn K, Mahner S, Meier W, Park-Simon TW, Grischke EM, Hillemanns P, Hilpert F, Lueck HJ, Kimmig R, Gropp-Meier M, Burges A, Jackisch C, Schroeder W, Pfisterer J (2020)

Publication Type: Conference contribution

Publication year: 2020

Journal

Publisher: KARGER

City/Town: BASEL

Pages Range: 87-87

Conference Proceedings Title: ONCOLOGY RESEARCH AND TREATMENT

Authors with CRIS profile

Involved external institutions

Universitätsklinikum Schleswig-Holstein (UKSH) Germany (DE) Technische Universität Dresden Germany (DE) Medizinische Hochschule Hannover (MHH) / Hannover Medical School Germany (DE) Klinikum der Universität München (Großhadern und Innenstadt) Germany (DE) Universitätsklinikum Ulm Germany (DE) Universitätsklinikum Heidelberg Germany (DE) Klinikum der Stadt Ludwigshafen am Rhein gGmbH Germany (DE) Universitätsklinikum Frankfurt am Main (KGU) Germany (DE) Philipps-Universität Marburg Germany (DE) Universitätsklinikum Essen Germany (DE) Kliniken Essen-Mitte Germany (DE) Charité - Universitätsmedizin Berlin Germany (DE) Universitätsklinikum Hamburg-Eppendorf (UKE) Germany (DE) Evangelisches Krankenhaus Düsseldorf Germany (DE) Sana Klinikum Offenbach Germany (DE) Universitätsklinikum Tübingen Germany (DE)

How to cite

APA:

Hanker, L., Harter, P., Sehoul, L., Rau, J., Canzler, U., Schmalfeldt, B.,... Pfisterer, J. (2020). Carboplatin/Pegylated Liposomal Doxorubicin/Bevacizumab (CD-Bev) vs. Carboplatin/Gemcitabine/Bevacizumab (CG-BEV) in Patients with Recurrent Ovarian Cancer: a Prospective Randomized Phase iii Engot/GCiG-Intergroup Study (Ago Study Group, Ago-AUSTRiA, ANZGOG,GiNECO, SGCTG). In ONCOLOGY RESEARCH AND TREATMENT (pp. 87-87). BASEL: KARGER.

MLA:

Hanker, Lars, et al. "Carboplatin/Pegylated Liposomal Doxorubicin/Bevacizumab (CD-Bev) vs. Carboplatin/Gemcitabine/Bevacizumab (CG-BEV) in Patients with Recurrent Ovarian Cancer: a Prospective Randomized Phase iii Engot/GCiG-Intergroup Study (Ago Study Group, Ago-AUSTRiA, ANZGOG,GiNECO, SGCTG)." Proceedings of the ONCOLOGY RESEARCH AND TREATMENT BASEL: KARGER, 2020. 87-87.

BibTeX: Download